A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study

BACKGROUND: Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or BRCA2. We studied the clinical activity and toxicity of veliparib in ovarian cancer patients carrying a germline BRCA1 or BRCA2 mutation (gBRCA). METHODS: Eligibili...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Coleman, Robert L., Sill, Michael W., Bell-McGuinn, Katherine, Aghajanian, Carol, Gray, Heidi J., Tewari, Krishnansu S., Rubin, Steven C., Rutherford, Thomas J., Chan, John K, Chen, Alice, Swisher, Elizabeth M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4447525/
https://ncbi.nlm.nih.gov/pubmed/25818403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.03.042
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados